Phibro Animal Health Corporation (Class A) (PAHC) exhibits 30.9% gross margins and 9.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 19.2x enterprise multiple and 4.8% implied options volatility.
Sustained 30.9% gross profitability converts into 8.5% operating margin and 9.9% ROIC, outpacing sector cost of capital.
ROIC: 9.9% // GM: 30.9%YoY revenue trajectory of +27.4% paired with 5.08% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +27.4% // FCF YLD: 5.08%Altman Z-Score of 2.87 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.87 // F-SCORE: 8/9Trading at 32.7x trailing P/E (27.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 32.7x // EV/EBITDA: 19.2xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $38.86 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 3.7% net margins.
NET MARGIN: 3.7% // D/E: 1.82x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for PAHC & activate live FRED threshold breach alerts.